Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection

Internal Medicine Journal

Volumn 46, Issue 3, 2016, Pages 281-287

  Gray, E L ^a   Goldberg, H F ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Drug induced liver injury; Isoniazid; Latent tuberculosis; Patient compliance; Rifampicin

Indexed keywords

AMINOTRANSFERASE; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; ISONIAZID INDUCED HEPATOXICITY; LATENT TUBERCULOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ADOLESCENT; AGE; AGED; BLOOD; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CONTROLLED STUDY; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CHILD, PRESCHOOL; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; LIVER FUNCTION TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84960097457     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12979     Document Type: Article

References (31)

1. Denholm J, McBryde E. Management of latent tuberculosis infections in Australia and New Zealand: a review of current practice. Tuber Res Treat 2010; 2010: 5.
2. Centers for Disease Control and Prevention. Targeted tuberculin skin testing and treatment of latent tuberculosis infection. Morb Mortal Wkly Rep 2000; 49: 1-54.
3. Comstock G. How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults. Int J Tuber Lung Dis 1999; 3: 847-50.
4. Hirsch-Moverman Y, Daftary A, Franks J, Colson P. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuber Lung Dis 2008; 12: 1235-54.
5. American Thoracic Society. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
6. Kucers A, Crowe S, Grayson M, Hoy J. The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs, 5 edn. London: Butterworth-Heinemann; 1997.
7. Sakhuja V, Jha V, Varna P, Joshi K, Chugh K. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996; 61: 211-15.
8. Aguado J, Herrero J, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G et al. Clinical presentation and outcome of tuberculosis in kidney, liver and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group. GESITRA. Transplantation 1997; 63: 1278-86.
9. Miller R, Lanza L, Kline J, Geist L. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995; 152: 374-6.
10. Meyers B, Halpern M, Sheiner P, Mendelson M, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994; 58: 301-6.
11. Carmona L, Gomez-Reino J, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola E et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumour necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72.
12. Keane J, Gershon S, Wise R, Mirabile-Levens E, Kasznica J, Schwieterman W et al. Tuberculosis associated with infliximab, a tumour necrosis factor a - neutralising agent. N Engl J Med 2001; 345: 1098-104.
13. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-22.
14. Wolfe F, Michard K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2010; 50: 372-9.
15. Menzies D, Dion M, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomised trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-9.
16. Menzies D, Long R, Trajman A, Dion M, Yang J, Al Jajdali H et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomised trial. Ann Intern Med 2008; 149: 689-97.
17. LoBue P, Moser K. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-7.
18. Jereb J, Etkind S, Joglar O, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003; 7: S384-90.
19. Lobato M, Leary L, Simone P. Treatment for latent TB in correctional facilities: a challenge for TB elimination. Am J Prev Med 2003; 24: 249-53.
20. Nolan C, Goldberg S, Buskin S. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 11: 1014-18.
21. Sprinson J, Flood J, Fan C, Shaw T, Pascopella L, Young J et al. Evaluation of tuberculosis contact investigations in California. Int J Tuberc Lung Dis 2003; 7: S363-8.
22. Jasmer R, Snyder D, Chin D, Hopewell P, Cuthbert S, Antonio Paz E et al. Twelve months of isoniazid compared with four months of rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 162: 1648-52.
23. Dobler C, Marks G. Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. PLoS One 2012; 7: e48900.
24. Mitchell J, Zimmerman H, Ishak K, Thorgerisson U, Timbrell J, Snodgrass W et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84: 181-92.
25. Scharer L, Smith J. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 71: 1113-20.
26. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatoxicity. Chest 2003; 123: 102-6.
27. Millard P, Wilcosky T, Reade-Christopher S, Weher D. Isoniazid-related fatal hepatitis. West J Med 1996; 164: 486-91.
28. Fountain F, Tolley E, Chrisman C, Self T. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7 year evaluation from a public health tuberculosis clinic. Chest 2005; 128: 116-23.
29. Dufour D, Lott J, Nolte F, Gretch D, Koff R, Seeff L. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis and monitoring. Clin Chem 2000; 46: 2050-68.
30. Dufour D, Lott J, Nolte F, Gretch D, Koff R, Seeff L. Diagnosis and monitoring of hepatic injury: I. Performance characteristics of laboratory tests. Clin Chem 2000; 46: 2027-49.
31. Kunst H, Khna K. Age-related risk of hepatoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010; 14: 1374-81.